Zizhong Hu1, Yun Su1, Ping Xie1, Lu Chen1, Jiangdong Ji1, Ting Feng2, Shaowei Wu2, Kang Liang1, Qinghuai Liu3. 1. Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu, 210029, People's Republic of China. 2. School of Electronic and Optic Engineering, Nanjing University of Science and Technology, Nanjing, 21000, China. 3. Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, No. 300, Guangzhou Road, Nanjing, Jiangsu, 210029, People's Republic of China. liuqh@njmu.edu.cn.
Abstract
PURPOSE: To quantify the preoperative neovascular change pattern on the fibrovascular membrane (FVM) within 7 days after intravitreal injection of conbercept (IVC) using optical coherence tomography angiography (OCTA) in proliferative diabetic retinopathy (PDR). METHODS: Prospective, observational study of PDR patients with visible FVM receiving or not receiving IVC. Neovascular changes were assessed by OCTA pre-IVC and 1, 3, 5, and 7 days post-IVC. Vessel skeleton density (SD) and vessel density (VD) were quantified by an intensity-based optical microangiography algorithm. The interclass correlation coefficient (ICC) was calculated to assess the agreement between measurements. The SD and VD were compared between follow-ups using repeated-measures analysis in the IVC group. RESULTS: The ICC was 0.992 (95% confidence interval [CI]: 0.982-0.996) for SD and 0.926 (95% CI: 0.838-0.912) for VD of neovascularization. The neovascularization on FVM significantly regressed in the IVC group (n = 16) compared with no IVC (n = 8) (p = 0.001 for SD and p < 0.001 for VD). The comparisons between consecutive follow-ups showed a statistically significant reduction in SD and VD at 1 and 3 days post-IVC. However, from day 3 onward, the SD and VD remained unchanged. There was no development or progression of tractional retinal detachment within the 7-day period after IVC. CONCLUSION: OCTA-based quantification of the neovascularization on FVM in PDR is feasible, with high inter-reader agreement. The regression of neovascularization reaches a plateau 3 days after IVC. CLINICAL TRIAL REGISTRATION: This trial is registered with the Chinese Clinical Trial Registry ( http://www.chictr.org.cn , registration number ChiCTR-IPR-17014160).
PURPOSE: To quantify the preoperative neovascular change pattern on the fibrovascular membrane (FVM) within 7 days after intravitreal injection of conbercept (IVC) using optical coherence tomography angiography (OCTA) in proliferative diabetic retinopathy (PDR). METHODS: Prospective, observational study of PDR patients with visible FVM receiving or not receiving IVC. Neovascular changes were assessed by OCTA pre-IVC and 1, 3, 5, and 7 days post-IVC. Vessel skeleton density (SD) and vessel density (VD) were quantified by an intensity-based optical microangiography algorithm. The interclass correlation coefficient (ICC) was calculated to assess the agreement between measurements. The SD and VD were compared between follow-ups using repeated-measures analysis in the IVC group. RESULTS: The ICC was 0.992 (95% confidence interval [CI]: 0.982-0.996) for SD and 0.926 (95% CI: 0.838-0.912) for VD of neovascularization. The neovascularization on FVM significantly regressed in the IVC group (n = 16) compared with no IVC (n = 8) (p = 0.001 for SD and p < 0.001 for VD). The comparisons between consecutive follow-ups showed a statistically significant reduction in SD and VD at 1 and 3 days post-IVC. However, from day 3 onward, the SD and VD remained unchanged. There was no development or progression of tractional retinal detachment within the 7-day period after IVC. CONCLUSION:OCTA-based quantification of the neovascularization on FVM in PDR is feasible, with high inter-reader agreement. The regression of neovascularization reaches a plateau 3 days after IVC. CLINICAL TRIAL REGISTRATION: This trial is registered with the Chinese Clinical Trial Registry ( http://www.chictr.org.cn , registration number ChiCTR-IPR-17014160).
Authors: Robert L Avery; Joel Pearlman; Dante J Pieramici; Melvin D Rabena; Alessandro A Castellarin; Ma'an A Nasir; Matthew J Giust; Robert Wendel; Arun Patel Journal: Ophthalmology Date: 2006-10 Impact factor: 12.079
Authors: Hazem A El-Sabagh; Walid Abdelghaffar; Ahmad M Labib; Carlos Mateo; Tarek M Hashem; Dalal M Al-Tamimi; Abdulhafez A Selim Journal: Ophthalmology Date: 2010-11-04 Impact factor: 12.079
Authors: Mohamad Amr Salah Eddin Abdelhakim; Tamer A Macky; Khaled Abdel Galil Mansour; Hassan Ali Mortada Journal: Ophthalmic Res Date: 2010-08-11 Impact factor: 2.892
Authors: Raffaello di Lauro; Pio De Ruggiero; Raffaella di Lauro; Maria Teresa di Lauro; Mario Rosario Romano Journal: Graefes Arch Clin Exp Ophthalmol Date: 2010-02-05 Impact factor: 3.117
Authors: Stanislao Rizzo; Federica Genovesi-Ebert; Emanuele Di Bartolo; Andrea Vento; Sofia Miniaci; George Williams Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-02-20 Impact factor: 3.117
Authors: J F Arevalo; M Maia; H W Flynn; M Saravia; R L Avery; L Wu; M Eid Farah; D J Pieramici; M H Berrocal; J G Sanchez Journal: Br J Ophthalmol Date: 2007-10-26 Impact factor: 4.638
Authors: D da R Lucena; J A S Ribeiro; R A Costa; J C Barbosa; I U Scott; L L de Figueiredo-Pontes; R Jorge Journal: Br J Ophthalmol Date: 2009-02-10 Impact factor: 4.638